Analysis of Severe COVID-19 among Children in Foshan, China

Author:

Chen Xiaoqian1,Liang Yongqi1,Xie Qiyuan1,Jiang Suhua1

Affiliation:

1. First People's Hospital of Foshan

Abstract

Abstract Background This study aimed to analyze the clinical characteristics, treatments, and prognosis of severe neurological impairment among children infected with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) following the change in epidemic prevention policy in China in December 2022.Methods A total of 9 pediatric patients with severe neurological impairment caused by SARS-CoV-2 infection from December 17, 2022 to December 31, 2022 in the First People’s Hospital of Foshan were retrospectively analyzed.Results Seven (71.43%) of the nine cases involved patients under the age of three, while the other two cases were older than three and had underlying medical conditions. All patients presented with fever and neurological symptoms such as disorders of consciousness and/or convulsive seizures. Besides, all patients showed sudden aggravation (e.g., fulminant cerebral edema) within 24 hours of fever, without respiratory symptoms (e.g., cough). Interleukin-6 (IL-6), lactate dehydrogenase (LDH) and D-dimer were significantly increased in all nine cases. Except for three patients who survived more than 48 hours after the first rescue treatment, five died within 48 hours after hospitalization, while one died of secondary bacterial infection after seven days of treatment. All patients suffered from shock rapidly after onset, and five patients developed multiple organ failure (respiratory, heart, liver, kidney and skeletal muscle) in a short time. In terms of in-hospital treatments, five cases were treated with glucocorticoids, three with intravenous immunoglobulin (IVIG), and two with blood purification and tocilizumab.Conclusion SARS-CoV-2 infection can cause severe neurological damage in pediatric patients. Hyperpyrexia, convulsion, and inflammatory factors could serve as early warning indicators. Administering glucocorticoids immunoglobulin, blood purification and tocilizumab might have some therapeutic effects, but further research is needed to establish their effectiveness.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3